Pryce Introduces Bill To Reimbuse For Orally Administered Cancer Drugs.
H. Lee Moffitt Cancer Designated A Comprehensive Cancer Center By NCI.
DeMets Receives Lectureship On Epidemiology From NIH.
Generic Paclitaxel Approval Withstands Court Challenge.
Obit: J. Gale Katterhagen, NCAB’s First Community Physician.
NCI Invites “Extraordinary Opportunities” For Research. Groups Planning Promotion Of Cancer Clinical Trials.
FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.
M. D. Anderson Buys Record System For In-Patient Services From Atlanta Firm.
Genetronics Phase II Trials For Head & Neck Completed.
Biomira Ends Agreement On Lymphoma Vaccine.
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”
